Patents Assigned to Merck
  • Patent number: 9987255
    Abstract: The present invention is directed to 5,5-bicyclic oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: June 5, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Kuduk, Nigel Liverton, Thomas S. Reger, Jason W. Skudlarek
  • Patent number: 9988600
    Abstract: The present invention relates to cell culture media comprising polymer embedded components. Some components show poor stability in dry powder cell culture media. Others are hygroscopic. Such components can be embedded into polymers to increase stability and reduce clumping.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: June 5, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Michael Howard Rayner-Brandes, Joerg Von Hagen
  • Patent number: 9988406
    Abstract: A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the crystalline form may be used in antibiotics.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 5, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Katharina Reichenbacher, Robert J. Duguid, Jacqueline A. Ware, Douglas Phillipson
  • Patent number: 9988391
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: June 5, 2018
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Srinivasa Karra, Yufang Xiao
  • Patent number: 9988397
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a method of inhibiting ERK2 in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Formula (I). The invention also provides a method for treating cancer in a patient in need of such treatment, said method comprising administering to said patient an effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: June 5, 2018
    Assignees: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTD
    Inventors: Phieng Siliphaivanh, David L. Sloman, David Witter, Umar Faruk Mansoor, Joseph Kozlowski, Ziping Liu, Jianmin Fu, Zhilong Wan, Wei Liu, Yimin Qian, Xianhai Huang
  • Publication number: 20180148648
    Abstract: The invention relates to lateral fluorinated reactive mesogens (RMs) comprising a tolane group, to mixtures and formulations comprising them, to polymers obtained form such RMs and RM mixtures, and the use of the RMs, RM mixtures and polymers in optical or electrooptical components or devices, like optical films for liquid crystal displays (LCDs).
    Type: Application
    Filed: May 2, 2016
    Publication date: May 31, 2018
    Applicant: Merck Patent GmbH
    Inventors: Graham SMITH, Mark GOEBEL, Kevin ADLEM, Sarah WHITEHOUSE, Tara PERRETT
  • Publication number: 20180147208
    Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or pharmaceutically acceptable salt thereofs, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 23, 2016
    Publication date: May 31, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Joie GARFUNKLE, Olga ORNOSKI, Dann L. PARKER, JR., Subharekha RAGHAVAN, Libo XU
  • Publication number: 20180148790
    Abstract: The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.
    Type: Application
    Filed: April 12, 2016
    Publication date: May 31, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mark Ayers, Jared Lunceford, Andrey Loboda, Michael Nebozhyn, Terrill K. McClanahan, Heather Hirsch
  • Publication number: 20180148453
    Abstract: The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: May 31, 2016
    Publication date: May 31, 2018
    Applicants: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.
    Inventors: Dong-Ming Shen, Michael P. Dwyer, Christopher J. Sinz, Deping Wang, Shawn J. Stachel, Daniel V. Paone, Ashley Forster, Richard Berger, Yili Chen, Yimin Qian, Shimin Xu, Chunmei Hu
  • Patent number: 9985226
    Abstract: The present invention relates to compounds of the formula (1) and (2) which are suitable for use in electronic devices, in particular organic electroluminescent devices.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Dominik Joosten, Arne Buesing
  • Patent number: 9981970
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is —C(?O) or —S(O)2—, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: May 29, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Pengcheng Patrick Shao, Arto K. Krikorian, Petr Vachal
  • Patent number: 9985220
    Abstract: The present application relates to a compound of a formula (I) which contains an indenocarbazole group, a carbazole group and an electron-deficient group bonded to the indenocarbazole group. The compound is suitable for use in electronic devices, in particular in organic electroluminescent devices.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Thomas Eberle, Anja Jatsch, Christof Pflumm, Jonas Valentin Kroeber, Rémi Manouk Anèmian
  • Patent number: 9982113
    Abstract: The present invention relates to an LDS-active additive for LDS plastics, to a polymer composition comprising an additive of this type, and to an article having metallized conductor tracks in which a polymeric basic body of the article or a polymeric coating on a basic body comprises an LDS additive of the said type.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Helge Bettina Kniess, Ulrich Quittmann, Silvia Rosenberger
  • Patent number: 9980966
    Abstract: The invention relates to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of Her2, and the use of such combinations for the treatment of cancer.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Erik Wilker, Andreas Machl, Remigiusz Kaleta
  • Patent number: 9981969
    Abstract: The present invention relates to Imidazole Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Y, R1 and R2 are as defined herein. The present invention also relates to compositions comprising at least one Imidazole Derivative, and methods of using the Imidazole Derivatives for inhibiting CYP450 3A. Inhibition of CYP450 3A can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: May 29, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Milana Maletic, Yunfu Luo, Zhiqi Qi, Chunsing Li, Tingting Yu, Richard Soll
  • Patent number: 9981925
    Abstract: Novel azaquinazoline carboxamide derivatives of formula (I) wherein W1, W2, W3, W4, R1, R2, R3 and m which are defined above, are p70S6K inhibitor, and can be employed, inter alia, for the treatment of hyperproliferative disorders.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Ruoxi Lan, Justin Potnick, Lizbeth Celeste Deselm, Mark W. Cronin, Jr., Constantin Neagu, Xiaoling Chen, Roch Boivin, Theresa L. Johnson, Andreas Goutopoulos
  • Patent number: 9983441
    Abstract: A liquid crystal display device includes: a polymer layer that controls the alignment of liquid crystal molecules on at least one of the first substrate and the second substrate. The polymer layer is formed by polymerizing one or more radical-polymerizable monomers added to the liquid crystal layer. At least one of the radical-polymerizable monomers is a compound represented by P-Sp1-Z2-A1-(Z1-A2)n1-Z3-Sp2-P. In an example encompassed by the formula, P represents a radical-polymerizable group. Sp1 and Sp2 each represent a direct bond or an alkylene group. A1 represents a divalent aromatic hydrocarbon group. A2 represents a phenylene group. Z1, Z2, and Z3 may be the same or different. At least one of Z1, Z2, and Z3 represents a direct bond, or an —NRCO— group or —CONR— group. R represents a hydrogen atom or a C1-C6 linear alkyl group or alkenyl group. n1 is 0 or 1.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: May 29, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Youhei Nakanishi, Masanobu Mizusaki, Takeshi Noma
  • Patent number: 9985211
    Abstract: The invention relates to novel conjugated polymers containing one or more [1,2,5]Thiadiazolo[3,4-e]isoindole-5,7-dione (TID) repeating units, to methods for their preparation and educts or intermediates used therein, to polymer blends, mixtures and formulations containing them, to the use of the polymers, polymer blends, mixtures and formulations as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising, or being prepared from, these polymers, polymer blends, mixtures or formulations.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: May 29, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Nicolas Blouin, Agnieszka Pron, Graham Morse, Lana Nanson, Michal Krompiec, Stephane Berny
  • Patent number: 9982044
    Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: May 29, 2018
    Assignees: ZYMOGENETICS INC., MERCK SERONO S/A
    Inventors: Kent Bondensgaard, Roland Beckmann
  • Patent number: D819199
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: May 29, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Angela M. Amend Kwasnik, Benjamin R. Bartfield, Peter Basile, Jeffrey C. Givand, Philip G. Green, Sharad Gupta, Christin L. O'Neill, Steven Carl Persak, Robert Stianchi, Ari Tao Adler, Florian Altmann, Thomas Junk, Florian Kössler, Martin Meier, Scott R. Mackie, Pernilla Danielsson